Mebendazole

CHEMBL685 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
295.3 g/mol
LogP
2.8
Phase
4

An antiparasitic medication primarily used to treat intestinal worm infections such as pinworms, roundworms, and hookworms, and is also being studied for potential anticancer properties. It works by disrupting the formation of microtubules in parasites and potentially in cancer cells.

Masse moléculaire

295,2900 g/mol

LogP

2,80

TPSA

84,10 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COC(=O)Nc1nc2cc(C(=O)c3ccccc3)ccc2[nH]1

InChI

InChI=1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)

Molecular Formula

C16H13N3O3

HBD / HBA

2 / 4

Liaisons Rotatives

4

Atomes Lourds

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

An antiparasitic medication primarily used to treat intestinal worm infections such as pinworms, roundworms, and hookworms, and is also being studied for potential anticancer properties. It works by disrupting the formation of microtubules in parasites and potentially in cancer cells.

Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.

Yes, Mebendazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL685. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 4030. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.